|

SynKIR-310 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Verismo Therapeutics1

Indications

  • Marginal Zone Splenic Lymphoma1
  • DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation1
  • Epstein-Barr Virus Positive DLBCL, Nos1
  • Indolent B-Cell Non-Hodgkin Lymphoma1
  • Aggressive B-Cell Non-Hodgkin Lymphoma1

Denver, Colorado1 trial

SynKIR-310 for Relapsed/Refractory B-NHL

Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.